Publication | Closed Access

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

Allogeneic Tumor VaccineTgf-β2 Antisense GeneTumor ImmunologyPhase Ii TrialMedicineImmunologyTherapeutic VaccineImmune Checkpoint InhibitorImmunotherapyOncologyRadiation OncologyLung Cancer